Swedish Orphan Biovitrum has entered a new partnership with Innate Pharma to run the TELLOMAK-3 Phase 3 trial for lacutamab in cutaneous T cell lymphoma. The agreement comes after a softer month for the stock, which is down about 3.4% over 30 days, though the year-to-date return stands at 33.3% and the one-year total shareholder return at 60.9%. The most followed narrative on Simply Wall St puts the company's fair value at SEK498.42 per share versus a last close of SEK440.40, implying the stock is 11.6% undervalued. Bulls point to the rare disease focus and the lacutamab deal as underappreciated strengths, while bears cite recent share price softness and execution risk. On valuation, the stock trades at 110.7 times earnings compared with 76.5 times for peers and 21.7 times for the wider European biotech industry, with a fair ratio of 50.3 times.
